Source: Annual Congress 2006 - Therapies and management in chronic airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. C. Creutzberg, H. J. Pennings, M. T. J. Groenen, E. F. M. Wouters (Horn, Maastricht, Netherlands). Effects of infliximab on systemic features in patients with COPD suffering from cachexia. Eur Respir J 2006; 28: Suppl. 50, 689

Member's Comments

No comment yet.

Related content which might interest you: Effects of infliximab on local and systemic inflammation in patients with COPD suffering from cachexia Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 Effect of infliximab on lung function and well-being in patients with refractory sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Systemic inflammation in patients with COPD and anemia of chronic disease Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 Effect of 2-Year therapy with Roflumilast in severe systemic inflammation in COPD with metabolic syndrome Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019 Treating systemic effects of COPD Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 Treating systemic effects of COPD Source: Annual Congress 2012 - PG9 Progress on the treatment of COPD Year: 2012 Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations Source: Eur Respir J, 53 (4) 1900147; 10.1183/13993003.00147-2019 Year: 2019 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The effect of statin therapy in patients with chronic obstructive airway disease Source: International Congress 2015 – COPD: notable points Year: 2015 Markers of T2-inflammation in patients with severe asthma and concomitant COPD Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease Year: 2020 Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Source: Eur Respir J 2001; 17: 337-342 Year: 2001 Association of systemic inflammation with clinical recovery in patients with acute exacerbation of COPD Source: Annual Congress 2011 - Phenotyping and monitoring of airway diseases Year: 2011 Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD biomarkers Year: 2013 Influence of statin therapy on exacerbation frequency in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation Year: 2012 Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021 Effect of azithromycin treatment on inflammation in COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009